PrepaCyte-CB yields the highest number of colony-forming units (CFUs).

1. Christianna Henderson, Jonathan Wofford, Kathy Fortune, Donna Regan. Evaluation of Processing Technologies for Umbilical Cord Blood (UCB). SLCBB data presented at the 14th Annual ISCT Meeting, 2010 May, Philadelphia, Pennsylvania.
 

Cord blood stem cells are processed to remove red blood cell contamination. PrepaCyte-CB provides the greatest reduction in red blood cell (RBC) contamination over other processing methods.

2. The International Society for Cellular Therapy, Telgraft Quarterly Newsletter, Vol. 15 No. 4, Winter 2008.

3. Donna Regan, Jonathan Wofford, Kathleen Fortune, Christianna Henderson, and Salem Akel. Clinical Evaluation of an Alternative Cord Blood Processing Method. SLCBB data presented at the AABB Annual Meeting, San Diego, CA, 2011.
 

PrepaCyte-CB recovers the greatest percentage of CD34+ stem cells from human umbilical cord blood.

4. Basford C, Forraz N, Habibollah S, Hanger K, McGuckin C. The cord blood separation league table: a comparison of the major clinical grade harvesting techniques for cord blood stem cells. International Journal Stem Cells. 2010 May; 3(1):32-45.
 

PrepaCyte-CB is the most flexible method, the only processing type where TNC and CD34+ recovery is not affected by the initial volume of the collected unit, leaving desired TNCs and stem cells unmodified and unaffected during cord blood processing.

Basford C, et al. The cord blood separation league table: a comparison of the major clinical grade harvesting techniques for cord blood stem cells.
 

PrepaCyte-CB processed samples have significantly greater clonogenic potential than all current methods.

Basford C, et al. The cord blood separation league table: a comparison of the major clinical grade harvesting techniques for cord blood stem cells.
 

The number of colony-forming units (CFUs) is currently the most accurate measurement used to determine stem cell potency and the potential for stem cell engraftment.

Basford C, et al. The cord blood separation league table: a comparison of the major clinical grade harvesting techniques for cord blood stem cells.

5. Yoo Kh, et al., “The impact of post-thaw colony-forming units-granulocyte/ macrophage on engraftment following unrelated cord blood transplantation in pediatric recipients.” Bone Marrow Transplant 2007;39:515-52.

6. Kristin M. Page, Lijun Zhang, Adam Mendizabal, Stephen Wease, Shelly Carter, Tracy Gentry, Andrew E. Balber, Joanne Kurtzberg. CFUs Strongly Predict Engraftment after UCBT. Biol Blood Marrow Transplant 17:1362-1374, 2011.
 

Prepacyte-CB processed cord blood units were used in over 350 transplants and the data suggests a 4-5 day reduction in engraftment time as compared with units processed with other technologies.

7. Donald Hudspeth, "Emerging Considerations for Cord Blood Transplantation". 2015 Cord Blood Symposium. San Francisco, CA, 2015.

Cryo-Cell International holds more cord blood patents than any other cord blood bank.

8. Cryo-Cell International, through its ownership in research affiliate, Saneron CCEL Therapeutics, research affiliate, holds more cord blood patents than any other cord blood bank.
 

More than 500,000 parents from 87 countries have chosen Cryo-Cell to store their baby’s cord blood.

9. Includes specimens from Cryo-Cell International's affiliates in Mexico and India.
 

The FDA recommends only citrate-based anticoagulants, such as CPD, for use in cord blood collection.

10. Center for Biologics Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services. Guidance for industry: minimally manipulated, unrelated allogeneic placental/umbilical cord blood intended for hematopoietic reconstitution for specified indications. http://www.fda.gov/downloads/BiologicsBloodVaccines/Guidances/Blood/UCM187144.p
 

If your baby’s stem cells are properly processed and stored, scientists believe they should last indefinitely.

11. Linden JV, Preti RA, Dracker R. New York state guidelines for cord blood banking. Journal of Hematotherapy. 1997:6:535-41.
 

Currently, cord blood has been used in the treatment of nearly 80 diseases.

12. Moise K Jr. Umbilical cord stem cells. Obstet Gynecol. 2005;106(6):1393-1407.
 

Obtaining matched stem cells, which are necessary for transplant, can be extremely difficult due to strict matching requirements.

Moise K Jr. Umbilical cord stem cells.
 

Cord blood can treat hematologic cancers, bone marrow failures, hemoglobinopathies, hematologic cancer, immune deficiencies, and genetic disorders.

Moise K Jr. Umbilical cord stem cells.
 

Different from a public bank where your stem cells can be given to another individual and not available for your family, family banking ensures your stem cells will be readily available for your family if needed.

13. Beatty PG, Boucher KM, Mori M, Milford EL. Probability of finding HLA-mismatched related or unrelated marrow or cord blood donors. Hum Immunol. 2000;61(8):834-840.
 

Leukemias and lymphomas that develop later in life may also be treated with your own cord blood.

14. O’Brien TA, Tiedemann K, Vowels MR. No longer a biological waste product: umbilical cord blood. Med J Aust. 2006 184(8):407-410.
 

Close to 35,000 transplants worldwide have been performed using cord blood stem cells.

15. Ballen KK, Verter F, Kurtzberg J. Umbilical cord blood donation: public or private? Bone Marrow Transplantation. June 1, 2015, 1-8.
 

Pre-clinical Cord Tissue Stem Cell Research for Parkinson’s Disease

14. Fu YS, Cheng YC, Lin MY, et al. Conversion of human umbilical cord mesenchymal stem cells in Wharton’s jelly to dopaminergic neurons in vitro: potential therapeutic application for Parkinsonism. Stem Cells. 2006;24(1):115-124. Epub 2005 August.
 

Pre-clinical Cord Tissue Stem Cell Research for Rheumatoid Arthritis

17. Liu Y, Mu R, Wang S, et al. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther. 2010;12(6):R210.
 

Pre-clinical Cord Tissue Stem Cell Research for Stroke

18. Ding DC, Shyu WC, Chiang MF, et al. Enhancement of neuroplasticity through upregulation of β1-integrin in human umbilical cord-derived stromal cell implanted stroke model. Neurobio Dis. 2007;27(3):339-353. Epub 2007 Jun 18.
 

Pre-clinical Cord Tissue Stem Cell Research for Heart Disease

19. Sodian R, Lueders C, Kraemer L, et al. tissue engineering of autologous human heart valves using cryopreserved vascular umbilical cord cells. Ann Thorac Surg. 2006;81(6):2207-2214.
 

Pre-clinical Cord Tissue Stem Cell Research for Alzheimer’s disease

20. Ende N, Chen R, Ende-Harris D. Human umbilical cord blood cells ameliorate Alzheimer’s disease in transgenic mice. Department of Pathology and Laboratory Medicine, University of Medicine and Dentistry of New Jersey, New Jersey Medical School. J Med. 2001:32(3-4):241-7.

21. Lee HJ, Lee JK, Lee H, Carter JE, Chang JW, Oh W, Yang YS, Suh JG, Lee BH, Jin HK, Bae JS. Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer’s disease mouse model through modulation of neuroinflammation. Neurobiol Aging. 2012 Mar;33(3): 588-602.
 

Pre-clinical Cord Blood Stem Cell Research for Type 1 Diabetes

22. Anzalone R, Lo Iacono M, Loria T, et al. Wharton’s jelly mesenchymal stem cells as canddates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes. Stem Cell Rev. October 23, 2010. [Epub ahead of print.]

23. National Institutes of Health, ClinicalTrials.gov. Umbilical Cord Blood Infusion to treat Type 1 Diabetes. http://clinicaltrials.gov/ct2/show/NCT00305344. Identifier NCT00305344.
 

Pre-clinical Cord Tissue Stem Cell Research for Liver Fibrosis

24. Tsai PC, Fu TW, Chen Ym, et al. The therapeutic potential of human umbilical mesenchymal stem cells from Wharton’s jelly in the treatment of rat liver fibrosis. Liver Transpl. 2009;15(5):484-495.
 

Pre-clinical Cord Tissue Stem Cell Research for Lung Cancer

25. Maurya DK, Doi C, Kawabata A, et al. Therapy with un-engineered naïve rat umbilical cord matrix stem cells markedly inhibits growth of murine lung adenocarcinoma. BMC Cancer. 2010:10:590.
 

Pre-Clinical Cord Tissue Stem Cell Research for Sports Injuries (cartilage)

26. Wang L, Tran I, Seshareddy K, et al. A comparison of human bone marrow-derived mesenchymal stem cells and human umbilical cord-derived mesenchymal stromal cells for cartilage tissue engineering. Tissue Eng. 2009:15(8)(pt A):2259-2266.
 

Pre-clinical Cord Blood Stem Cell Research for Cerebral Palsy

27. Duke University: Phase I clinical trial using autologous cord blood to treat children with cerebral palsy. Kurtzberg J, Status of a clinical trial of autologous cord blood stem cells for the treatment of cerebral palsy and other acquired brain injuries in young children. Poster presented at: 9th annual International Umbilical Cord Blood Transplantation Symposium; June 3-5, 2010; San Francisco, CA.

28. Duke University: Phase II clinical trial using autologous cord blood to treat children with cerebral palsy. National Institute of Health, ClinicalTrials.gov. A randomized study of autologous umbilical cord blood reinfusion in children with cerebral palsy. http://clinicaltrials.gov/ct2/show/NCT1147653. Identifier NCT01147653.
 

Pre-clinical Cord Blood Stem Cell Research for Autism

29. Duke University: Autologous Umbilical Cord Blood Infusion for Children with Autism Spectrum Disorder (ASD). National Institutes of Health, ClinicalTrials.gov. Autologous Umbilical Cord Blood Infusion for Children with Autism Spectrum Disorder (ASD). https://clinicltrials.gov/ct2/show/NCT02176317.
 

Currently, the odds of undergoing any stem cell transplant by age 70 is 1 in 217.

30. Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the US. Biol. Blood Marrow Transplant. 2008;14:314-22.
 

$100,000 and $75,000 Quality Guarantees

31. Subject to the Terms and Conditions of our contract agreement, if the child’s cryopreserved cord blood was processed with our Premium PrepaCyte-CB processing method and fails to engraft in a stem cell transplant, Cryo-Cell will pay the Client $100,000; if the processing method was our standard HES processing method and fails to engraft, Cryo-Cell will pay the Client $75,000.

Best Price Guarantee

32. Cryo-Cell International guarantees to match any written offer for product determined to be similar at Cryo-Cell International’s sole discretion.
 

PrepaCyte-CB provides the greatest reduction in red blood cell (RBC) contamination, over other processing methods, including automated processing methods.

33. Alcaina, P. Solves, V. Mirabet, D. Planelles, A. Blanquer, L. Larrea, and R. Roig. "Comparison between Two Automatic Devices for Cord Blood Volume Reduction." 37th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT), Paris, France, Apr. 2011.
 

Research has shown that blood-derived stem cells from older donors undergo signs of aging that reduce their ability to function as well as stem cells from younger donors.

34. Gary van Zant, Ying Liang, Concise Review: Hematopoietic Stem Cell Aging,Life Span, and Transplantation. Stem cells Translational Medicine 2012;1:651–657.

35. Mechanisms that regulate Stem Cell Aging and Life Span, Cell Stem Cell 2013 Feb 7; 12(2): 152-65
 

Following the FDA recommendation, Cryo-Cell International uses heparin-free bags to safeguard clients from complications linked to heparin toxicity and allergy reaction, as well as to maximize the recovery of stem cells

36. Recommended in U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for Industry: Minimally Manipulated, Unrelated, Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic Reconstitution for Specified Indications, published October 2009. It states, “During collection of cord blood, we recommend that you use an appropriate closed, sterile container sealed in a manner that prevents cell loss and contamination. We recommend that you use only citrate-based anticoagulants.”

37. Publication discussing benefit of CPD as compared to Heparin: Blood (ASH Annual Meeting Abstracts) American Society of Hematology “Cord Blood Units Collected with Liquid CPD Appear to Contain Significantly More Nucleated and CD34+ Cells Than Units Collected with Dry Heparin” Morey Kraus*, 1, Karen Foster*, 2, Asimena Rigas Bridges*, 3 and Mark C. Walters, MD 4 2009 114: Abstract 4227 http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/4227

Siblings have up to a 75% chance of being a match for each other

38. Beatty PG,  et al. Probability of finding HLA-mismatched related or unrelated marrow or cord blood donors.
 

Umbilical cord blood mesenchymal stem cells have been demonstrated to promote wound healing and have been clinically applied for the treatment of skin ulcers. Studies clearly showed the benefits of umbilical cord blood mesenchymal stem cells for wound healing.

39. Luo, G. et al. Promotion of cutaneous wound healing by local application of mesenchymal stem cells derived from human umbilical cord blood. Wound repair and regeneration: official publication of the Wound Healing Society [and] the European Tissue Repair Society 18, 506–513, 10.1111/j.1524-475X.2010.00614.x (2010).
 

Cord tissue mesenchymal stem cells have the ability to regenerate and differentiate into many different types of cells and therefore, they can potentially be used to treat more conditions than cord blood alone can treat.

40. El Omar et al, Umbilical Cord Mesenchymal Stem Cells: The New Gold Standard for Mesenchymal Stem Cell-Based Therapies? Tissue Eng Part B Rev. April 2014 (Epub ahead of print).
 

MSC’s have been used in clinical trials to complement the cord blood stem cells in the same transplant.

41. Taghizadeh RR, Pollok KE, Betancur M, et al. Wharton’s jelly derived mesenchymal stem cells: regenerative medicine beyond umbilical cord blood. Presented at: First Meeting of the Placenta Stem Cell Society (IPLASS). From Fetomaternal Tolerance to Immunomodulary Properties of Placenta-Derived Cells in Cell Therapy [poster abstract]; October 3–6, 2010; Brescra, Italy. [As measured by CD45+].
 
42. Wu K., Sheu J., Wu H., Tsai C., Sieber M., Peng C., Chao Y. “Cotransplantation of Umbilical Cord-Derived Mesenchymal Stem Cells Promote Hematopoietic Engraftment in Cord Blood Transplantation: A Pilot Study.” Transplantation Journal 95.5 (2013): 773-777.
 

Cryo-Cell International’s cord tissue cryopreservation processing method has been independently acknowledged as the best in the industry according to scientific data published in the October, 2015 issue of the journal Placenta.

43. Magda Dulugiac, Lucia Moldovan, Otilia Zarnescu. Comparative studies of mesenchymal stem cells derived from different cord tissue compartments-The influence of cryopreservation and growth media. Placenta. 2015 Oct;36(10):1192-203. doi: 10.1014/j.placenta.2015.08.011. Epub 2015 Aug 29.
 

Stem cells derived from cord tissue are being utilized in regenerative medicine for a wide range of conditions and are currently being investigated in hundreds of clinical trials.

44. Taghizadeh RR, Cetrulo KJ, Cetrulo CL. Wharton's Jelly stem cells: future clinical applications. Placenta. 2011 Oct;32 Suppl 4:S311-5. Epub 2011 Jul 6. Review. PubMed PMID:21733573.
 

According to results from the New York Blood Center, AXP processing leads to 70% red blood cell reduction.

45.  Kim, C., Wilke-Douglas, M., Sivilotti, M. (2015). “Meta-Analysis of the AXP® and Sepax® Automated Cord Blood Processing Systems.” Cesca Therapeutics, 380118[A].

According to a study done at the Memorial Sloan Kettering Cancer Center, stem cell units from a FACT accredited lab produce better treatment outcomes for patients.

46. Barker, Juliet N. "Using CD34+ Cell Dose in Cord Blood Unit Selection. "Emerging Considerations for Cord Blood Transplantation (2015): n. pag. Web. Director, Cord Blood Transplant Program Memorial Sloan-Kettering Cancer Center.
 

The 10 top Cancer Centers in the U.S. are all FACT accredited.

47. "FACT: Foundation for the Accreditation of Cellular Therapy." What FACT Accreditation Means To Patients. N.p., n.d. Web. 02 Sept. 2015.
 

Heparin disrupts and impairs the functional capacity of cells used for cardiovascular repair.

48. Seeger, F.H., Rasper, T., Fischer, A., Muhly–Reinholz, M., Hergenreider, E., Leistner, D.M., Sommer, K., Manavski, Y., Henschler, R., Chavakis, E., Assmus, B., Zeiher, A.M., and Dimmeler, S. "Heparin Disrupts the CXCR4/SDF-1 Axis and Impairs the Functional Capacity of Bone Marrow– Derived Mononuclear Cells Used for Cardiovascular Repair." N.p., July 2012. Web. 01 Sept. 2015.
 

Stem cells can lose viability and functionality when exposed to extreme temperatures

49. Wierenga, P.K., Brenner, M.K., and Konings, A.W.T. (1998) Bone Marrow Transplantation 21:73–78

Symonds, R.P., Wheldon, T.E., Clarke, B., and Bailey, G. (1981) Br. J. Cancer 44:682–691.
 

There has been a call by the scientific community to store additional aliquots of cord blood and a move to improve the science of expansion in order to broaden the availability of usage and doses.

50. Rosenau, Emma H., Michele W. Sugrue, Michael Haller, Diann Fisk, Susan S. Kelly, Myron Chang, Wei Hou, Lamis Eldjerou, William Slayton, Christopher R. Cogle, and John R. Wingard. “Characteristics of Thawed Autologous Umbilical Cord Blood.” Transfusion 52.10 (2012): 2234–242.

Haller, M. J., C. H. Wasserfall, K. M. Mcgrail, M. Cintron, T. M. Brusko, J. R. Wingard, S. S. Kelly, J. J. Shuster, M. A. Atkinson, and D. A. Schatz. “Autologous Umbilical Cord Blood Transfusion in Very Young Children With Type 1 Diabetes.” Diabetes Care 32.11 (2009): 2041–046.
 

Parents consider stored cord blood to be a valuable resource, and some parents may not allow their children to take part in clinical trials in fear that they will deplete their cord blood supply

51. Driscoll, Kimberly A., Suzanne Bennett Johnson, Desmond A. Schatz, and Michael J. Haller. “Use of a Precious Resource: Parental Decision Making about Using Autologous Umbilical Cord Blood in Studies Involving Young Children with Type 1 Diabetes.” Contemporary Clinical Trials 32.4 (2011): 524–29.

Expand collections and support self-renewal in hematopoietic stem cells like those found in cord blood is a major goal of experimental and clinical science

52. Conneally, E., J. Cashman, A. Petzer, and C. Eaves “Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic–scid/scid mice.”Proceedings of the National Academy of Sciences 94.18 (1997): 9836–9841.

UM171 enables a “robust” expansion of cord blood stem cells

53. Fares I, Chagraoui J, Gareau Y, et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science. 2014;345(6203):1509–1512.

Of the 209 entries in ClinicalTrials.gov that are open cord blood trials, only 118 are cell therapies with cord blood

54. "Counting Keywords Is Not Compiling Clinical Trials: Alternative Facts about Cell Therapy and Venture Capital." CellTrials.org. n.d. Web. 20 Mar. 2017.

Median time to absolute neutrophil count (ANC) of 500 for PrepaCyte-CB is 16 days and for HES is 20 days.

55. Assessment of Hetastarch and PrepaCyte-CB in Transplanted Cord Blood Units. Poster presented at: ICBS 2017. 15th Annual International Cord Blood Symposium; 2017 June 8–10; San Diego, California.

Median time to absolute neutrophil count (ANC) of 500 for AXP is 20 days.

56. U.S. Food and Drug Administration. (n.d.). Retrieved June 15, 2017, from https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM279612.pdf

Median time to absolute neutrophil count (ANC) of 500 for Sepax is 21 days.

57. U.S. Food and Drug Administration. (n.d.). Retrieved June 15, 2017, from https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM322732.pdf

Median time to absolute neutrophil count (ANC) of 500 for Sepax/HES processed at Bloodworks is 21.5 days

58. U.S. Food and Drug Administration. (n.d.). Retrieved June 15, 2017, from https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM483861.pdf

Median time to absolute neutrophil count (ANC) of 500 for Sepax/HES processed at ClinImmune Labs is 25 days

59. U.S. Food and Drug Administration. (n.d.). Retrieved June 15, 2017, from https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM305761.pdf